Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Director | January 01, 2024 | January 03, 2024 |
| IceCure Medical Ltd.ICCM · Entity 8100 | Director | March 18, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2034-01-01 | Direct | 108,333 |
Reported balance
After 2024-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 108,333 · Balance 108,333 F1: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.
IceCure Medical Ltd.
Report date March 18, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary sharesSEC Table I · non-derivative | Direct | 296,631 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 296,631 F1: Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-01-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share. F2: The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2029-05-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F5: The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share. F4: The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2030-10-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F7: The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share. F6: The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2032-01-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F9: The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. F8: The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51 · Expires 2033-02-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F11: The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share. F10: The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) 10,000 ordinary shares, and (ii) 286,631 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 107,486 RSUs have vested and 179,631 remain unvested as of March 18, 2026.
F2: The options were granted on January 10, 2018, and vested in equal quarterly installments of 6.25% beginning on December 5, 2017. As of March 18, 2026, all 95,295 options are fully vested.
F3: The options were granted with an exercise price of NIS 4.8 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.55 per share.
F4: The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 25,000 options are fully vested.
F5: The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.
F6: The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.
F7: The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share.
F8: The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 110,000 options are fully vested.
F9: The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
F10: The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 44,471 options are vested.
F11: The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Big Digital Energy, Inc.
Report date November 07, 2018 · Filed June 12, 2019
Section 16 reporting ended · disclosed 2019-06-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2024 Filed Jan 3, 2024 21:15 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 108,333 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001178913-24-000049 · zk2430733.xml · derivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,333 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares Expires 2034-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:16 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000051 · zk2328962.xml · derivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:07 UTC | Entera Bio Ltd. ENTX · Entity 5464 | PurchaseOrdinary Shares, par value NIS 0.0000769 per share | 7,000 | $2.80 | $19,600.00 |
DisclosureSEC source: 0001178913-22-000167 · zk2227079.xml · nonDerivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:09 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000091 · zk2227045.xml · derivative · entry 2 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:09 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000091 · zk2227045.xml · derivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:39 UTC | Big Digital Energy, Inc. WIZP · Entity 673 | GrantStock Option (right to buy) · Derivative | 46,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005273 · f4040418mayron_wizepharma.xml · derivative · entry 2 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,500 shares Expires 2025-04-04 F4 · price: The Stock Option was granted as compensation for services as the Chairman of the Board of the Issuer. F3 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:39 UTC | Big Digital Energy, Inc. WIZP · Entity 673 | GrantRestricted Stock Units (RSUs) | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-005273 · f4040418mayron_wizepharma.xml · nonDerivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,259 F1 · kind: The RSUs were fully vested upon grant. F2 · price: The RSUs were granted as compensation for services as the Chairman of the Board of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.